BURNETT JOSEPH sold $1.1M of CLPT

BURNETT JOSEPH (CEO and President) sold 60,000 shares of ClearPoint Neuro, Inc. (CLPT) at $17.79 ($1.07M total) on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BURNETT JOSEPH
Published Jun 22, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLPT
Neutral
medium confidence
Mentioned
$CLPT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLPTNeutralLow
01

Why it matters

The newest concrete fact is the CEO’s open-market sale of 60,000 shares at a stated price, with holdings after the transaction and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 framing reduces the likelihood of a durable negative fundamental interpretation.

03

What to watch

The filing does not indicate whether other insiders or the company announced concurrent catalysts; without follow-on news, the signal is mostly sentiment/positioning rather than fundamentals.

Relevance 5/10Novelty 5/10Timing: Form 4 filed June 22 (sale dated June 17)

Background

The article is an SEC Form 4 insider transaction disclosure for ClearPoint Neuro, Inc. (CLPT).

Company-level read

Ticker impact

$CLPTNeutralMedium confidence
Context

ClearPoint Neuro CEO Joseph Burnett sold 60,000 shares at $17.79 under a 10b5-1 plan, disclosed via Form 4 filed June 22.

Expected impact

Likely limited near-term price impact; any reaction should fade unless accompanied by other news.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction is explicitly under a pre-arranged 10b5-1 plan and provides no new operating/financial information.

Market effects

No clear sector read-across; this is company-specific insider transaction data.

None.

None.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations; traders may overreact to the headline sale size.

Key entities

  • ClearPoint Neuro, Inc.

    Issuer of the Form 4 insider transaction; CEO Joseph Burnett sold shares under a 10b5-1 plan.

  • Joseph Burnett

    CEO and President; reported open-market sale of 60,000 shares on June 17, 2026.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLPTMed

ClearPoint Neuro (CLPT) Q3 2026 Earnings Call Transcript

ClearPoint Neuro (CLPT) reported Q3 2026 revenue of $12.1M, up 36% YoY, driven by growth in neurosurgery navigation and capital equipment sales. The company used its ATM facility to raise $22M, ending the quarter with $46.2M in cash. CLPT supports uniQure's BLA submission for Huntington's disease treatment, aiming for parallel FDA approvals. The company is preparing for increased Phase III trials and commercial product launches in 2027.

$CLPTMed

What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call

ClearPoint Neuro (CLPT) reported Q3 operating expenses of $13.4M, down from $17M in Q2. Cash reserves were $46.2M, with $22M raised via equity offering. CEO Burnett expects reduced operating burn and capital expenditures. The company awaits FDA decision on AMT-130 submission, with potential parallel approvals for drug and device. ClearPoint outlined four growth pillars, including biologics, neurosurgery navigation, and laser therapy.

$CLPTMed

ClearPoint Neuro Reports Third Quarter 2026 Results

ClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ClearPoint Neuro Reports Third Quarter 2026 Results Neurosurgery Navigation & Therapy Grew 59% to $5.4 Million SOLANA BEACH, CA, October 28, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offerin